2004 Morton K. Schwartz Award for Significant Contributions in Cancer Research Diagnostics
Daniel W. Chan, PhD, DABCC, FACB, is Professor of Pathology, Oncology, Radiology, and Urology at the Johns Hopkins University School of Medicine, and Director of the Clinical Chemistry Division and Co-Director of the Pathology Core Laboratory of Johns Hopkins Hospital in Baltimore, Maryland. Dr. Chan is the also Director of the Biomarker Discovery Center, Johns Hopkins University.
Dr. Chan received his BA degree in Biology from the University of Oregon and his PhD in Biochemistry from the State University of New York at Buffalo. He completed his clinical chemistry postdoctoral training at the Erie County Laboratories. He began his clinical chemistry career in 1977 at the Johns Hopkins University School of Medicine as Assistant Professor of Laboratory Medicine and Assistant Director of the Clinical Chemistry Laboratories of Johns Hopkins Hospital. Four years later, he became the Director of the Clinical Chemistry Division. He is actively involved in undergraduate and postgraduate education for students of medicine, clinical chemistry, and clinical pathology.
Dr. Chan is a diplomat of the American Board of Clinical Chemistry, a fellow of the National Academy of Clinical Biochemistry (NACB), and an active member of several professional societies. He has served on the board of directors of the NACB and as president of the National Registry in Clinical Chemistry. He is currently serving on the editorial boards of Journal of Clinical Immunoassay, International Journal of Biological Markers, Clinical Chemistry and Laboratory Medicine, and Clinical Proteomics and is a former editorial board member of Clinical Chemistry.
The focus of Dr. Chan’s research is the development and application of proteomic and immunologic techniques in the diagnosis, management, and understanding of cancer. His work has demonstrated the importance of analytical methodologies for tumor markers, endocrine, or clinical chemistry assays to determine the clinical outcomes of a patient’s disease process. He is an internationally recognized expert in immunoassay, clinical proteomics, and biochemical tumor markers. In the area of prostate cancer, Dr. Chan was one of the first investigators to demonstrate the clinical usefulness of various molecular forms of prostate-specific antigen (PSA) in the diagnosis and management of prostate cancer patients. He performed the original clinical study and published the findings (in the Journal of Clinical Oncology) leading to the first Food and Drug Administration-cleared serum breast cancer test (CA27.29). For 4 years, Dr. Chan served as the director and principal investigator of the Tumor Markers Research Laboratory & Analytical Clinical Chemistry Laboratory at Johns Hopkins Singapore Pte., Ltd., in Singapore. He is the founder and director of the Johns Hopkins Biomarker Discovery Center, which uses novel proteomic technologies to identify and validate biomarkers for cancer. He recently published several journal articles on the use of SELDI mass spectrometry to discover serum biomarkers in ovarian, breast, pancreatic, and prostate cancers.
Dr. Chan has edited and written five books on immunoassay, immunoassay automation, diagnostic endocrinology, and tumor markers. He has published more than 200 articles, including the tumor marker chapters in the Tietz Textbook of Clinical Chemistry and in Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications, which he also co-edited.
Dr. Chan is actively involved in the Human Proteome Organization (HUPO) and its Plasma Proteome Initiative. He serves as chairman of a HUPO committee responsible for the development of reference specimens for a global comprehensive study of the human proteome.